Sava raises €16.6M Series A round

31 July 2025· London, United Kingdom· health, digital_health, biosensors, wearables, b2c, software_hardware

The funding will be used to accelerate regulatory approval and commercialisation of its next-generation wearable, as well as scale its growing team, grow its team, increase manufacturing capacity, and fast-track the regulatory process for its first product, a pain-free, affordable, and accurate Continuous Glucose Monitor (CGM).

Investors

LeadBalderton Capital
Also participating
Italian Founders FundNorrsken VCJamJar InvestmentsExceptional VenturesAthletico VenturesPentland VenturesTrue

About Sava

Stage
Series A
Headquarters
London, United Kingdom
Founded
2019
Team Size
51–200
Sectors
healthdigital_healthbiosensorswearablesb2csoftware_hardware

Source: https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHYSjC76uSpvAUX4MGgy67Hfjq2V39J0sKFoLlbCBaQnu-t2PQH5cXXyPEo2bzpz_uH5p00tlQ8FufbXDfCMc8C96zLwmzDpzbtm-FhJ2E2E34DWkgn-i1ADmbmVpo07dIyJOus3E__3MX-iWelLTC1NUKi_FMdkCkJkioJoYLlwO7OhHp7lXq6qxskoFqaDahXlkeLajGAkfYCDGFxMK1ByLGuYebtRuy8gbk__uYU8JvxOiBS91Ty6Is-tZFc_My0CsHbO1mMbecSlV1yB2bplX3TCI7z5U17lA==